AFT Pharmaceuticals (NZE:AFT, ASX:AFP) expects to achieve record sales of more than AU$200 million in fiscal 2025, up from AU$56 million in fiscal 2015 and AU$106 million in fiscal 2020, according to a Monday filing with the Australian and New Zealand bourses.
The upbeat outlook comes despite sales disruptions seen in the first half. The pharmaceutical company said it targets to achieve AU$300 million turnover on a rolling annual basis by the end of 2027.
AFT Pharmaceuticals' Kiwi shares were up past 1% in recent Monday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。